Strategy to targeting the immune resistance and novel therapy in colorectal cancer

Assessing the CRC subtypes that can predict the outcome of colorectal cancer (CRC) in patients with immunogenicity seems to be a promising strategy to develop new drugs that target the antitumoral immune response. In particular, the disinhibition of the antitumoral T‐cell response by immune checkpoi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gang, Wang, Wang, Jun‐Jie, Guan, Rui, Yan, Sun, Shi, Feng, Zhang, Jia‐Yan, Li, Zi‐Meng, Gao, Jing, Fu, Xing‐Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943429/
https://www.ncbi.nlm.nih.gov/pubmed/29658188
http://dx.doi.org/10.1002/cam4.1386

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943429/
https://www.ncbi.nlm.nih.gov/pubmed/29658188
http://dx.doi.org/10.1002/cam4.1386

Ejemplares similares